Shrooms to treat depression? It’s been a hot topic for many years; however, a medical establishment uncomfortable with psychedelics and subsequent government interference have inhibited progress. But it looks like the grip may be loosening. So treating depression with psilocybin: an introduction…
Those mushrooms contain psilocybin, a hallucinogenic chemical compound. Psilocybin has fueled many a spiritual and recreational trip. But now it’s getting renewed attention as a potential treatment for emotional and mental disorders.
Happened upon a fascinating, new article in the journal Nature. In his piece, “Will psychedelics be a ‘revolution in psychiatry’?”, science journalist Asher Mullard interviews neuropsychopharmacologist Dr. David Nutt. Dr. Nutt is a professor at Imperial College London and is the chairman of Drug Science, a non-profit he founded to provide independent, evidence-based information on drugs. Nutt has been a controversial figure over the years, his views at times ruffling professional and political feathers. Is that a bad thing?
Mr. Mullard opens his article by pointing out that trial design considerations, regulatory hurdles, and economics continue to present barriers for psychedelic-assisted therapies. He goes on to say that in the 1970s, early in Dr. Nutt’s career, there was evidence that psychedelics could work wonders in mental health. However, the medical establishment was overly concerned about the perceived dangers of mind-altering agents. As a result, governments made the compounds illegal, and research into potential therapeutic uses came to a halt.
According to Mullard, Nutt and others have continued to advocate for open-mindedness, as a growing body of evidence supports the view that psychedelics could provide a much needed boost for psychiatric medicine.
For instance, phase III trial results for MDMA (Ecstasy) in the treatment of PTSD show the drug, in conjunction with psychotherapy, improved outcomes. Though Dr. Nutts’ phase II trial of psilocybin for the treatment of depression missed its primary end point, progress was made on several fronts and research work continues. In fact, if you go to ClinicalTrials.gov and enter psilocybin in “Other terms,” you’ll get details on 66 studies, featuring a variety of emotional/mental situations.
By the way, if you’re interested in participating in a psilocybin clinical trail, why not head over to the ClinicalTrials site, pick out a study that fits, and reach out to the contact person?
Okay, what you’re about to read comes from Dr. Nutt in response to Mullard’s questions. No way could I include content from the entire interview. I just want to bring you a quality psilocybin for depression introduction. And you can do some digging if you’d like to learn more.
Psilocybin and depression
As Dr. Nutt was discussing his dosing of patients with psilocybin in the 2000s, he stated his work with psychedelics was an effort to understand the psychedelic state. Nutt observed that the brain’s cerebral cortex is full of 5-HT (serotonin) receptors, so it’s important to understand what they’re doing. Why are they there? How will psilocybin effect them?
Through the work, Nutt and his team learned that parts of the brain related to depression can actually be turned off. And it was then that they seriously began to think about the therapeutic uses of psilocybin.
Dr. Nutt continues to believe psychedelics are going to be a revolution in psychiatry. But hear me, psychotherapy will be, has to be, a key component of any psychedelic regimen.
Psilocybin versus antidepressants
It’s Dr. Nutt’s opinion that psilocybin works faster, better on most measures, and has a different and slightly better side-effect profile than current antidepressants. And that’s because there are fundamental differences in the way the drugs work.
Nutt used selective serotonin reuptake inhibitor (SSRI) antidepressants for purposes of comparison. He explained that SSRIs work on 5-HT1A receptors in the limbic system (located beneath the cerebral cortex). The action allows the brain to heal from the effects of chronic stress. He described it as putting a plaster cast on a broken leg to support the bone until it heals.
He went on to say the psychedelics, which include psilocybin, work in the cerebral cortex via 5-HT2A receptors. The action disrupts the repetitive negative thinking that’s so troubling in depression. Nutt referred to it as resetting the brain’s thinking process. He also mentioned that impacting the 5-HT2A receptor seems to be very powerful in terms of driving neuroplasticity, a miraculous natural healing dynamic.
In summary, Dr. Nutt stated that psilocybin’s mechanism of action is at the network level. The mechanism of action for the SSRIs occurs at the synapse level.
Let’s wrap it up
In case you aren’t aware, there isn’t a whole lot to write home about concerning the drug development pipeline for the mood and anxiety disorders. And that’s why research work has to continue with the psychedelics, including psilocybin. There’s way too much at stake.
But as much promising evidence as there’s been over the years pertaining to the psychedelics, questions remain. Dr. Nutt from the article…
“How do you sustain wellness after a psychedelic? Okay, so people get better. But do they stay well? And how do you maximize staying well? Do you keep giving psychedelics or do you put people on an SSRI, or in psychotherapy?”
Let’s find out.
Be sure to read the entire interview with Dr. Nutt in Nature: Will psychedelics be ‘a revolution in psychiatry’?
brain image: Chegg Prep
I’m inviting you to review the hundreds upon hundreds of Chipur articles. Whole lot of learning going on.